Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 230

1.

Reduced-dose intramuscular ketamine for severe agitation in an academic emergency department.

O'Brien ME, Fuh L, Raja AS, White BA, Yun BJ, Hayes BD.

Clin Toxicol (Phila). 2019 Jul 23:1-5. doi: 10.1080/15563650.2019.1643468. [Epub ahead of print]

PMID:
31335216
2.

Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers.

Stewart A, Coker EA, Pölsterl S, Georgiou A, Minchom AR, Carreira S, Cunningham D, O'Brien ME, Raynaud FI, de Bono JS, Al-Lazikani B, Banerji U.

Mol Cancer Ther. 2019 Aug;18(8):1396-1404. doi: 10.1158/1535-7163.MCT-18-0727. Epub 2019 Jul 1.

PMID:
31262731
3.

Loss of skin elasticity is associated with pulmonary emphysema, biomarkers of inflammation, and matrix metalloproteinase activity in smokers.

O'Brien ME, Chandra D, Wilson RC, Karoleski CM, Fuhrman CR, Leader JK, Pu J, Zhang Y, Morris A, Nouraie S, Bon J, Urban Z, Sciurba FC.

Respir Res. 2019 Jun 24;20(1):128. doi: 10.1186/s12931-019-1098-7.

4.

Bronchoalveolar Lavage Cell Gene Expression in Severe Asthma Reveals Mechanisms of Severe Disease and Influences of Medications.

Weathington N, O'Brien ME, Radder JE, Whisenant TC, Bleecker ER, Busse WW, Erzurum SC, Gaston B, Hastie AT, Jarjour NN, Meyers DA, Milosevic J, Moore WC, Tedrow JR, Trudeau JB, Wong HP, Wu W, Kaminski N, Wenzel SE, Modena BD.

Am J Respir Crit Care Med. 2019 Jun 4. doi: 10.1164/rccm.201811-2221OC. [Epub ahead of print]

PMID:
31161938
5.

Age-related cardiovascular outcomes in older adults receiving epinephrine for anaphylaxis in the emergency department.

O'Brien ME, Koehl JL, Raja AS, Erickson TB, Hayes BD.

J Allergy Clin Immunol Pract. 2019 May 10. pii: S2213-2198(19)30444-1. doi: 10.1016/j.jaip.2019.04.040. [Epub ahead of print] No abstract available.

PMID:
31078763
6.

Prolonged Cold Ischemia Induces Necroptotic Cell Death in Ischemia-Reperfusion Injury and Contributes to Primary Graft Dysfunction after Lung Transplantation.

Wang X, O'Brien ME, Yu J, Xu C, Zhang Q, Lu S, Liang L, An X, McDyer JF, Mallampalli RK.

Am J Respir Cell Mol Biol. 2019 Aug;61(2):244-256. doi: 10.1165/rcmb.2018-0207OC.

PMID:
30742487
7.

FBXO17 promotes cell proliferation through activation of Akt in lung adenocarcinoma cells.

Suber TL, Nikolli I, O'Brien ME, Londino J, Zhao J, Chen K, Mallampalli RK, Zhao Y.

Respir Res. 2018 Oct 25;19(1):206. doi: 10.1186/s12931-018-0910-0.

8.

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors.

O'Brien MER, Sarker D, Bhosle J, Thillai K, Yap TA, Uttenreuther-Fischer M, Pemberton K, Jin X, Wiebe S, de Bono J, Spicer J.

Cancer Chemother Pharmacol. 2018 Nov;82(5):757-766. doi: 10.1007/s00280-018-3661-1. Epub 2018 Aug 7.

9.

nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial.

Gridelli C, Chen T, Ko A, O'Brien ME, Ong TJ, Socinski MA, Postmus PE.

Drug Des Devel Ther. 2018 May 24;12:1445-1451. doi: 10.2147/DDDT.S155750. eCollection 2018.

10.

Wife Caregiver Experiences in the Patient with Prostate Cancer at Home.

O'Brien ME, Steele NM.

Urol Nurs. 2017 Jan-Feb;37(1):37-44.

PMID:
29240364
11.

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments.

Minchom A, Thavasu P, Ahmad Z, Stewart A, Georgiou A, O'Brien MER, Popat S, Bhosle J, Yap TA, de Bono J, Banerji U.

PLoS One. 2017 Oct 5;12(10):e0186106. doi: 10.1371/journal.pone.0186106. eCollection 2017.

12.

Risk factors for totally implantable venous access device-associated complications in cystic fibrosis.

McCarthy C, O'Carroll O, O'Brien ME, McEnery T, Franciosi A, Gunaratnam C, McElvaney NG.

Ir J Med Sci. 2018 May;187(2):429-434. doi: 10.1007/s11845-017-1672-2. Epub 2017 Aug 15.

PMID:
28812224
13.

Proteomic analysis of bronchoalveolar lavage fluid (BALF) from lung cancer patients using label-free mass spectrometry.

Hmmier A, O'Brien ME, Lynch V, Clynes M, Morgan R, Dowling P.

BBA Clin. 2017 Mar 6;7:97-104. doi: 10.1016/j.bbacli.2017.03.001. eCollection 2017 Jun.

14.

Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit.

Papadatos-Pastos D, Roda D, De Miguel Luken MJ, Petruckevitch A, Jalil A, Capelan M, Michalarea V, Lima J, Diamantis N, Bhosle J, Molife LR, Banerji U, de Bono JS, Popat S, O'Brien MER, Yap TA.

Eur J Cancer. 2017 Apr;75:56-62. doi: 10.1016/j.ejca.2016.12.026. Epub 2017 Feb 17.

PMID:
28214659
15.

Targeting the PD-1/PD-L1 axis in non-small cell lung cancer.

Kumar R, Collins D, Dolly S, McDonald F, O'Brien MER, Yap TA.

Curr Probl Cancer. 2017 Mar - Apr;41(2):111-124. doi: 10.1016/j.currproblcancer.2016.12.002. Epub 2016 Dec 23. Review.

PMID:
28214087
16.

A randomised study comparing the effectiveness of acupuncture or morphine versus the combination for the relief of dyspnoea in patients with advanced non-small cell lung cancer and mesothelioma.

Minchom A, Punwani R, Filshie J, Bhosle J, Nimako K, Myerson J, Gunapala R, Popat S, O'Brien ME.

Eur J Cancer. 2016 Jul;61:102-10. doi: 10.1016/j.ejca.2016.03.078. Epub 2016 May 6.

PMID:
27156228
17.

Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer.

Weller A, O'Brien MER, Ahmed M, Popat S, Bhosle J, McDonald F, Yap TA, Du Y, Vlahos I, deSouza NM.

Eur J Cancer. 2016 May;59:65-78. doi: 10.1016/j.ejca.2016.02.017. Epub 2016 Mar 24. Review.

PMID:
27016624
18.

Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.

Shah MH, Lorigan P, O'Brien ME, Fossella FV, Moore KN, Bhatia S, Kirby M, Woll PJ.

Invest New Drugs. 2016 Jun;34(3):290-9. doi: 10.1007/s10637-016-0336-9. Epub 2016 Mar 9.

19.

A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients.

Kumar R, Lu SK, Minchom A, Sharp A, Davidson M, Gunapala R, Yap TA, Bhosle J, Popat S, O'Brien ME.

Cancer Chemother Pharmacol. 2016 Feb;77(2):375-83. doi: 10.1007/s00280-015-2950-1. Epub 2015 Dec 26.

PMID:
26706729
20.

The BLT1 Inhibitory Function of α-1 Antitrypsin Augmentation Therapy Disrupts Leukotriene B4 Neutrophil Signaling.

O'Dwyer CA, O'Brien ME, Wormald MR, White MM, Banville N, Hurley K, McCarthy C, McElvaney NG, Reeves EP.

J Immunol. 2015 Oct 15;195(8):3628-41. doi: 10.4049/jimmunol.1500038. Epub 2015 Sep 14.

21.

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.

Kelly K, Altorki NK, Eberhardt WE, O'Brien ME, Spigel DR, Crinò L, Tsai CM, Kim JH, Cho EK, Hoffman PC, Orlov SV, Serwatowski P, Wang J, Foley MA, Horan JD, Shepherd FA.

J Clin Oncol. 2015 Dec 1;33(34):4007-14. doi: 10.1200/JCO.2015.61.8918. Epub 2015 Aug 31.

22.

Impact of Time Lapse on ASCP Board of Certification Medical Laboratory Scientist (MLS) and Medical Laboratory Technician (MLT) Examination Scores.

ASCP Board of Certification Research and Development Committee, Brown KA, Fenn JP, Freeman VS, Fisher PB, Genzen JR, Goodyear N, Houston ML, O'Brien ME, Tanabe PA.

Lab Med. 2015 Summer;46(3):e53-8. doi: 10.1309/LMNM534LIACPBZWH.

PMID:
26286580
23.

Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064).

O'Brien ME, Gaafar R, Hasan B, Menis J, Cufer T, Popat S, Woll PJ, Surmont V, Georgoulias V, Montes A, Blackhall F, Hennig I, Schmid-Bindert G, Baas P; EORTC-LCG.

Eur J Cancer. 2015 Aug;51(12):1511-28. doi: 10.1016/j.ejca.2015.04.026. Epub 2015 Jun 11.

24.

The impact of smoke exposure on the clinical phenotype of alpha-1 antitrypsin deficiency in Ireland: exploiting a national registry to understand a rare disease.

O'Brien ME, Pennycooke K, Carroll TP, Shum J, Fee LT, O'Connor C, Logan PM, Reeves EP, McElvaney NG.

COPD. 2015 May;12 Suppl 1:2-9. doi: 10.3109/15412555.2015.1021913.

PMID:
25938284
25.

Non-Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of (18)F-FDG Uptake at PET-Association with Treatment Response and Prognosis.

Cook GJ, O'Brien ME, Siddique M, Chicklore S, Loi HY, Sharma B, Punwani R, Bassett P, Goh V, Chua S.

Radiology. 2015 Sep;276(3):883-93. doi: 10.1148/radiol.2015141309. Epub 2015 Apr 17.

PMID:
25897473
26.

An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12 and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of severe neutropenic toxicity.

Minchom AR, Saksornchai K, Bhosle J, Gunapala R, Puglisi M, Lu SK, Nimako K, Coward J, Yu KC, Bordi P, Popat S, O'Brien ME.

BMJ Open Respir Res. 2014 Dec 11;1(1):e000061. doi: 10.1136/bmjresp-2014-000061. eCollection 2014.

27.

Lung cancer screening: Is there a future?

O'Brien ME.

Indian J Med Paediatr Oncol. 2014 Oct;35(4):249-52. doi: 10.4103/0971-5851.144984.

28.

A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors.

Kendra KL, Plummer R, Salgia R, O'Brien ME, Paul EM, Suttle AB, Compton N, Xu CF, Ottesen LH, Villalona-Calero MA.

Mol Cancer Ther. 2015 Feb;14(2):461-9. doi: 10.1158/1535-7163.MCT-14-0431. Epub 2014 Dec 10.

29.

The effect of the decoy molecule PA401 on CXCL8 levels in bronchoalveolar lavage fluid of patients with cystic fibrosis.

McElvaney OJ, O'Reilly N, White M, Lacey N, Pohl K, Gerlza T, Bergin DA, Kerr H, McCarthy C, O'Brien ME, Adage T, Kungl AJ, Reeves EP, McElvaney NG.

Mol Immunol. 2015 Feb;63(2):550-8. doi: 10.1016/j.molimm.2014.10.013. Epub 2014 Nov 2.

PMID:
25453468
30.

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.

von Pawel J, Jotte R, Spigel DR, O'Brien ME, Socinski MA, Mezger J, Steins M, Bosquée L, Bubis J, Nackaerts K, Trigo JM, Clingan P, Schütte W, Lorigan P, Reck M, Domine M, Shepherd FA, Li S, Renschler MF.

J Clin Oncol. 2014 Dec 10;32(35):4012-9. doi: 10.1200/JCO.2013.54.5392. Epub 2014 Nov 10.

PMID:
25385727
31.

A 76 year old female diagnosed with cystic fibrosis.

O'Brien ME, Murphy DM, Plant BJ.

Ir Med J. 2014 Sep;107(8):240-1.

PMID:
25282963
32.

Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data.

Rossi A, Chiodini P, Sun JM, O'Brien ME, von Plessen C, Barata F, Park K, Popat S, Bergman B, Parente B, Gallo C, Gridelli C, Perrone F, Di Maio M.

Lancet Oncol. 2014 Oct;15(11):1254-62. doi: 10.1016/S1470-2045(14)70402-4. Epub 2014 Sep 14. Review.

PMID:
25232001
33.

Alpha-1 antitrypsin augmentation therapy corrects accelerated neutrophil apoptosis in deficient individuals.

Hurley K, Lacey N, O'Dwyer CA, Bergin DA, McElvaney OJ, O'Brien ME, McElvaney OF, Reeves EP, McElvaney NG.

J Immunol. 2014 Oct 15;193(8):3978-91. doi: 10.4049/jimmunol.1400132. Epub 2014 Sep 12.

34.

Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation.

Hasan B, Greillier L, Pallis A, Menis J, Gaafar R, Sylvester R, Fennell DA, Baas P, Surmont V, Van Meerbeeck JP, O'brien ME.

Eur J Cancer. 2014 Nov;50(16):2771-82. doi: 10.1016/j.ejca.2014.07.020. Epub 2014 Aug 21.

PMID:
25155251
35.

AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines.

Puglisi M, Thavasu P, Stewart A, de Bono JS, O'Brien ME, Popat S, Bhosle J, Banerji U.

Lung Cancer. 2014 Aug;85(2):141-6. doi: 10.1016/j.lungcan.2014.05.008. Epub 2014 Jun 2.

PMID:
24957682
36.

Increased outer arm and core fucose residues on the N-glycans of mutated alpha-1 antitrypsin protein from alpha-1 antitrypsin deficient individuals.

McCarthy C, Saldova R, O'Brien ME, Bergin DA, Carroll TP, Keenan J, Meleady P, Henry M, Clynes M, Rudd PM, Reeves EP, McElvaney NG.

J Proteome Res. 2014 Feb 7;13(2):596-605. doi: 10.1021/pr400752t. Epub 2013 Dec 13.

PMID:
24328305
37.

Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).

O'Brien ME, Gaafar RM, Popat S, Grossi F, Price A, Talbot DC, Cufer T, Ottensmeier C, Danson S, Pallis A, Hasan B, Van Meerbeeck JP, Baas P.

Eur J Cancer. 2013 Sep;49(13):2815-22. doi: 10.1016/j.ejca.2013.05.008. Epub 2013 Jun 20.

PMID:
23791541
38.

Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinoma.

Gennatas S, Stanway SJ, Thomas R, Min T, Shah R, O'Brien ME, Popat S.

BMC Cancer. 2013 Apr 26;13:207. doi: 10.1186/1471-2407-13-207.

39.

A pilot study of a novel home telemonitoring system for oncology patients receiving chemotherapy.

Nimako K, Lu SK, Ayite B, Priest K, Winkley A, Gunapala R, Popat S, O'Brien ME.

J Telemed Telecare. 2013 Apr;19(3):148-152. Epub 2013 May 23.

PMID:
23615717
40.

The PARAMOUNT study and the re-challenge chemotherapy issue in advanced non-small cell lung cancer.

Cufer T, O'Brien ME.

Eur J Cancer. 2013 Jun;49(9):2269-70. doi: 10.1016/j.ejca.2013.02.038. Epub 2013 Mar 24. No abstract available.

PMID:
23535271
41.

Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years.

Cufer T, Ovcaricek T, O'Brien ME.

Eur J Cancer. 2013 Apr;49(6):1216-25. doi: 10.1016/j.ejca.2012.11.021. Epub 2012 Dec 19. Review.

PMID:
23265700
42.

Pulmonary Mycobacterium szulgai infection.

McSweeney FG, O'Brien ME, Sheehan S, Plant B, Corcoran G.

Ir Med J. 2012 Sep;105(8):275-7.

PMID:
23155916
43.

Patient factors, health care factors and survival from lung cancer according to ethnic group in the south of London, UK.

Nimako K, Gunapala R, Popat S, O'Brien ME.

Eur J Cancer Care (Engl). 2013 Jan;22(1):79-87. doi: 10.1111/j.1365-2354.2012.01373.x. Epub 2012 Jun 28.

PMID:
22738286
44.

Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma.

Blayney JK, Ceresoli GL, Castagneto B, O'Brien ME, Hasan B, Sylvester R, Rudd R, Steele J, Busacca S, Porta C, Mutti L, O'Byrne KJ, Scullin P, Gaafar R, Baas P, Van Meerbeeck J, Fennell DA.

Eur J Cancer. 2012 Nov;48(16):2983-92. doi: 10.1016/j.ejca.2012.05.018. Epub 2012 Jun 15.

PMID:
22704893
45.

How do lung cancer specialists follow their patients with stage III non-small cell lung cancer (NSCLC) after definitive treatment? A short report.

Yumuk PF, Mohammed N, Maat AP, Fink C, Marchal B, O'Brien ME.

Eur J Cancer. 2012 Sep;48(14):2163-5. doi: 10.1016/j.ejca.2012.04.006. Epub 2012 May 26.

PMID:
22633748
46.

A phase II study of ¹⁸F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva); objective and symptomatic responses at 6 and 12 weeks.

O'Brien ME, Myerson JS, Coward JI, Puglisi M, Trani L, Wotherspoon A, Sharma B, Cook G, Ashley S, Gunapala R, Chua S, Popat S.

Eur J Cancer. 2012 Jan;48(1):68-74. doi: 10.1016/j.ejca.2011.10.033. Epub 2011 Nov 24.

PMID:
22119198
47.

Establishing an EGFR mutation screening service for non-small cell lung cancer - sample quality criteria and candidate histological predictors.

Leary AF, Castro DG, Nicholson AG, Ashley S, Wotherspoon A, O'Brien ME, Popat S.

Eur J Cancer. 2012 Jan;48(1):61-7. doi: 10.1016/j.ejca.2011.09.022. Epub 2011 Oct 27.

PMID:
22036089
48.

Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib.

Popat S, Vieira de Araújo A, Min T, Swansbury J, Dainton M, Wotherspoon A, Lim E, Nicholson AG, O'Brien ME.

J Thorac Oncol. 2011 Nov;6(11):1962-3. doi: 10.1097/JTO.0b013e31822eec5e. No abstract available.

49.

Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease--a short communication.

Calderone R, Nimako K, Leary A, Popat S, O'Brien ME.

Eur J Cancer. 2011 Jul;47(11):1603-5. doi: 10.1016/j.ejca.2011.05.008. Epub 2011 Jun 16.

PMID:
21684152
50.

Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062.

O'Brien ME, Konopa K, Lorigan P, Bosquee L, Marshall E, Bustin F, Margerit S, Fink C, Stigt JA, Dingemans AM, Hasan B, Van Meerbeeck J, Baas P.

Eur J Cancer. 2011 Oct;47(15):2322-30. doi: 10.1016/j.ejca.2011.05.020. Epub 2011 Jun 16.

PMID:
21684151

Supplemental Content

Loading ...
Support Center